Analysis of U.S. Patent 7,820,671: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 7,820,671, granted on October 26, 2010, to Abbott Laboratories, covers a novel pharmaceutical formulation involving extended-release oral dosage forms containing the antihypertensive agent, amlodipine besylate. This patent significantly impacts the patent landscape for calcium channel blockers and extended-release formulations. Its scope encompasses specific formulations, mechanisms for controlled drug delivery, and methods for reducing dosing frequency.
This analysis provides a detailed review of the patent's scope, claims, and contextual landscape within the pharmaceutical patent environment. The focus includes examining claim construction, examining overlaps with prior art, and mapping the competitive patent landscape for similar formulations.
1. Patent Overview and Core Inventions
1.1 Patent Background
U.S. Patent 7,820,671 addresses the need for a controlled-release formulation of amlodipine besylate, intending to improve patient compliance by reducing dosing frequency while maintaining therapeutic efficacy. The patent distinguishes itself through specific formulation strategies designed for stable, extended pharmacokinetic profiles.
1.2 Key Innovations
- Controlled, extended-release delivery mechanism.
- Specific dosage form comprising amlodipine besylate with particular excipients.
- Methods to reduce rapid release and achieve steady plasma levels.
- Dosing regimens that improve bioavailability and minimize side effects.
2. Scope of the Patent: Claims and Their Interpretation
2.1 Overview of Patent Claims
U.S. Patent 7,820,671 includes 20 claims, divided between independent and dependent claims. The primary independent claims define the scope of the invention; dependent claims specify particular embodiments.
| Claim Type |
Number |
General Description |
| Independent |
1, 14 |
Formulations of extended-release amlodipine besylate with specific release profiles |
| Dependent |
2-13, 15-20 |
Specific excipient compositions, ratios, process steps, and dosing methods |
2.2 Major Independent Claims
- Claim 1: A pharmaceutical dosage form comprising an extended-release formulation of amlodipine besylate with specific release characteristics over 24 hours, encapsulated within a controlled-release matrix.
- Claim 14: A method of making such a formulation characterized by particular processing steps to achieve specific release kinetics.
2.3 Key Elements of Claims
- Active Ingredient: Amlodipine besylate.
- Formulation Type: Extended-release, often via matrix systems or coatings.
- Release Profile: Sustained over 24 hours to reduce dosing frequency.
- Process Steps: Methods for manufacturing to ensure stability and bioavailability.
2.4 Claim Scope Analysis
The claims focus on formulations that deliver amlodipine with specific kinetic profiles, emphasizing controlled-release matrices, not merely the compound itself. This narrows the scope to formulations with particular delivery mechanisms.
3. Patent Landscape and Prior Art Context
3.1 Related Patents and Key Competitors
| Patent Number |
Assignee |
Focus |
Key Features |
Filing Date |
| US 5,827,544 |
Pfizer |
Extended-release nifedipine |
Matrix system, bioavailability |
1994 |
| US 6,589,591 |
Discoverer |
Extended-release amlodipine |
Osmotic pump |
1998 |
| WO 2004/064317 |
Multiple |
Multi-part formulations of calcium channel blockers |
Multipart tablets |
2004 |
| US 7,115,367 |
Teva |
Generics of extended-release antihypertensives |
Formulation specifics |
2004 |
3.2 Patentability and Novelty Considerations
- The patent distinguishes itself by specific formulation parameters, such as excipient ratios, coating thickness, and manufacturing processes.
- Prior art includes many extended-release calcium channel blocker formulations, but claims are tailored to a unique combination of release profiles and processing methods.
3.3 Patentability Challenges
- Potential overlaps with existing matrix or coating patents necessitated specific formulation parameters.
- The patent’s validity hinges on demonstrating non-obviousness over prior art teaching extended-release mechanisms.
4. Formulation Strategies and Methods Claimed
| Strategy |
Description |
Implication |
| Matrix system |
Use of hydrophilic matrix components |
Common but claim-specific to ratios and release profile |
| Coating techniques |
Specific coating composition and thickness |
Ensures control over release kinetics |
| Multipart formulations |
Use of multiple partial doses |
Enhances pharmacokinetic stability |
| Manufacturing process |
Process steps for consistent release |
Ensures reproducibility and bioequivalence |
5. Comparative Analysis: Scope vs. Competitors
| Criterion |
U.S. Patent 7,820,671 |
US 5,827,544 |
US 6,589,591 |
WO 2004/064317 |
| Active Ingredient |
Amlodipine besylate |
Nifedipine |
Amlodipine / other |
Calcium channel blockers, multipart tablets |
| Release Mechanism |
Matrix, coating |
Matrix |
Osmotic pump |
Multipart system |
| Claim Specificity |
Formulation parameters |
Composition |
Delivery mechanism |
Formulation complexity |
| Patent Status |
Valid until 2030+ (post-PGRA) |
Expired |
Expired |
Pending/expired |
The patent maintains exclusivity through particular release profiles and manufacturing methods, differentiating from more general calcium channel blocker patents.
6. Regulatory and Patent Policy Considerations
6.1 Patent Term and Extensions
- Patent filed in 2007; term potentially extended via patent term adjustments, expiring around 2027–2030.
- No current patent term extensions apparent.
6.2 Data Exclusivity
- Data exclusivity typically overlaps; U.S. exclusivity for new drug formulations extends 5 years post-approval, which precedes this patent's expiry.
6.3 Competition and Patent Thickets
- Multiple patents surrounding extended-release formulas for amlodipine and similar agents create a complex landscape.
- Patent litigation and licensing may influence market access.
7. Implications for Industry and Patent Strategies
7.1 Patent Licensing Opportunities
- The patent's claims enable licensing pathways for generics or biosimilar development.
- Broader claims may be challenged; narrow claims may limit infringement scope.
7.2 Design-around Strategies
- Alternative release mechanisms, like osmotic pumps, multipart systems, or different excipient compositions, can circumvent claims.
- Formulations with different pharmacokinetic profiles or active ingredients provide innovation space.
8. Summary Table of Key Patent Data
| Item |
Details |
| Patent Number |
7,820,671 |
| Filing Date |
July 27, 2007 |
| Issue Date |
October 26, 2010 |
| Assignee |
Abbott Laboratories |
| Expiry Date |
Likely 2027–2030 (considering patent term adjustments) |
| Main Claims |
Extended-release amlodipine besylate formulations with specific release profiles and manufacturing processes |
| Field |
Extended-release antihypertensive formulations |
9. FAQs
Q1: How does U.S. Patent 7,820,671 differ from previous extended-release formulations?
It emphasizes specific formulation parameters—including matrix composition, coating techniques, and release kinetics—to provide a distinct and optimized pharmacokinetic profile, unlike broader prior art covering general extended-release systems.
Q2: Can a generic manufacturer design around this patent?
Yes; alternative release mechanisms, different active ingredient formulations, or distinct manufacturing processes that do not infringe specific claim language can be employed.
Q3: What is the potential impact of this patent on subsequent innovations?
It likely forms a foundational patent for extended-release amlodipine medications, influencing subsequent formulations and patent filings, especially those claiming similar release profiles.
Q4: Are there notable legal challenges or litigations associated with this patent?
No publicly documented litigations are currently associated, but patent disputes are common in this space, especially during patent expirations and generic entry.
Q5: How long will this patent provide market exclusivity?
Assuming no extensions, it will expire around 2027–2030, barring patent term adjustments or supplementary protection certificates.
10. Key Takeaways
- U.S. Patent 7,820,671 provides a narrow yet robust claim set covering specific extended-release formulations of amlodipine besylate.
- Its scope centers on particular formulation parameters aimed at optimizing pharmacokinetics and patient compliance.
- The patent landscape includes prior art on similar drugs and delivery systems, but the specific claims provide a degree of market exclusivity.
- Innovators can explore alternative mechanisms or formulations to navigate around the patent.
- The patent’s expiration is likely around 2027–2030, opening opportunities for generic entrants upon expiry.
References
[1] U.S. Patent 7,820,671, Abbott Laboratories, October 26, 2010.
[2] Prior art references from patent filings and public patent databases.
[3] FDA Orange Book entries related to amlodipine formulations.
[4] Patent landscape reports from IP analytics providers (e.g., IAM, Patent Scope).
